FluoroPharma Medical, Inc. (FPMI)

[hmoney]

Interesting comment on the yahoo mb by a supposed dr.... take it for what its worth

"Phase II data will be published by the end of the summer
I participated in the recent private placement to fund the balance of the Cardio-Pet Trial and the full BF Pet trial. I recently had dinner with Thijs Spoor while he was in Chicago visiting a few money managers. Two things stand out as key value creators. First, the industry is virtually unknown because imaging agent production is a very closed community. FPMI is the only public company with patents on pipeline drugs. The few producers of SPECT low resolution imaging drugs are divisions of large companies. This is important because the valuations are supported by all players. There is a Japanese Pharmaceutical company currently selling $200 million of the low resolution imaging agent for the SPECT market invented by the same PHD that developed the FPMI high resolution PET imaging agents. This Japanese Pharma company is very interested in adding the Cardio-pet imaging agent to their portfolio of licensed products. They have known about the ongoing development of the Cardio-Pet imaging agent since 2004. It seems probable that a licensing deal of some sort would follow shortly after Phase II data is published in the August time frame.

The industry values both the Cardio-Pet and the BF Pet imaging drugs at $200 million each after Phase II trial data is published. Together, the industry will value the FPMI drugs at $400 million later this year. With a current market cap of only $23 million, FPMI is significantly undervalued. Obviously, the obscurity of this market goes a long way to explain how something could trade at such a discount. Very few people know about FluoroPharma but that is changing rather quickly. The recent appointment of Andrew Sassine to the BOD creates visibility in the right circles. One thing I am quite sure about is that the buying over the last two months has come from people who very much understand the magnitude of the discount to true value of these two imaging drugs. Full value is $12 per share in August. I too am expecting $4 to $6 in 2014."

http://finance.yahoo.com/mbview/threadview/?&bn=92bca517-455f-3995-93fe-78b3187eafe2&tid=1395192826861-f0535638-64fc-498d-b8dd-37a0c9663796&tls=la%2Cd%2C0%2C3